Is AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)

Rare Chance to Be an Early Investor in AI Energy Breakthrough Technology expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors.

Geoffrey M. Parker net worth and biography

Geoffrey Parker Biography and Net Worth

Director of ChemoCentryx

Mr. Parker has served as a member of the ChemoCentryx Board of Directors since December 2009. Since September 2010, Mr. Parker has served as the Senior Vice President and Chief Financial Officer of Anacor after serving in a consulting capacity since December 2009. From July 2009 to July 2010, Mr. Parker served in a consulting capacity as the Chief Business Officer of InteKrin Therapeutics, a privately held biopharmaceutical company in Los Altos, California. From 1997 to April 2009, Mr. Parker was a Vice President, then Managing Director and finally Partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was Vice President at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors of Genoptix, Inc., a specialized laboratory service provider and ChemoCentryx, Inc., a clinical stage privately held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in Engineering Sciences and Economics and an M.B.A. from Stanford University.

What is Geoffrey M. Parker's net worth?: The estimated net worth of Geoffrey M. Parker is at least $42.61 million as of January 30th, 2024. Mr. Parker owns 819,590 shares of ChemoCentryx stock worth more than $42,610,484 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Parker may own. Learn More about Geoffrey M. Parker's net worth.
How do I contact Geoffrey M. Parker?: The corporate mailing address for Mr. Parker and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected]. Learn More on Geoffrey M. Parker's contact information.
Has Geoffrey M. Parker been buying or selling shares of ChemoCentryx?: Geoffrey M. Parker has not been actively trading shares of ChemoCentryx during the last quarter. Most recently, Geoffrey M. Parker sold 1,910 shares of the business's stock in a transaction on Thursday, March 4th. The shares were sold at an average price of $60.20, for a transaction totalling $114,982.00. Following the completion of the sale, the director now directly owns 111,913 shares of the company's stock, valued at $6,737,162.60. Learn More on Geoffrey M. Parker's trading history.
Who are ChemoCentryx's active insiders?: ChemoCentryx's insider roster includes Tausif Butt (COO), Markus Cappel (Treasurer), Thomas Edwards (Director), Susan Kanaya (CFO), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Geoffrey M. Parker Insider Trading History at ChemoCentryx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2021	Sell	1,910	$60.20	$114,982.00	111,913
3/23/2020	Sell	30,000	$36.70	$1,101,000.00	104,189
5/30/2019	Sell	12,815	$12.00	$153,780.00	85,014
5/13/2016	Buy	40,000	$4.03	$161,200.00	13,514
1/11/2016	Buy	20,000	$4.63	$92,600.00	13,514
12/11/2015	Buy	20,000	$7.25	$145,000.00	13,514
12/6/2013	Buy	20,000	$5.15	$103,000.00

Geoffrey M. Parker Buying and Selling Activity at ChemoCentryx

ChemoCentryx Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Today's Range

Now: $51.99

$51.99

50 Day Range

MA: $51.95

$51.66

$51.99

2 Week Range

Now: $51.99

$14.95

$52.00

Volume

113 shs

Average Volume

1,681,906 shs

Market Capitalization

$3.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22